BiotechTube

TD-9855 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurogenic Orthostatic Hypotension

Conditions

Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension

Trial Timeline

Sep 9, 2017 → Nov 28, 2018

NCT ID
NCT02705755

About TD-9855 + Placebo

TD-9855 + Placebo is a phase 2 stage product being developed by Theravance Biopharma for Neurogenic Orthostatic Hypotension. The current trial status is completed. This product is registered under clinical trial identifier NCT02705755. Target conditions include Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02705755Phase 2Completed

Competing Products

20 competing products in Neurogenic Orthostatic Hypotension

See all competitors
ProductCompanyStageHype Score
MirabegronAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
MirabegronAstellas PharmaPhase 1
33
mirabegronAstellas PharmaPhase 3
77
SAF312 + Placebo to SAF312NovartisPhase 2
52
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from FreiburgPfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)PfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
alfuzosin (SL770499)SanofiPhase 3
76
Alfuzosin + PlaceboSanofiPhase 3
76
Droxidopa capsules + Placebo capsulesLundbeckApproved
82
Rec 0/0438 1 mg or Rec 0/0438 2 mg + placeboRecordatiPhase 1/2
38
Ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetineTheravance BiopharmaPhase 3
72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin PlaceboTheravance BiopharmaPhase 1
28
AmpreloxetineTheravance BiopharmaPhase 1
28

Other Products from Theravance Biopharma

TelavancinApproved
80
umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg + Placebo ( Revefenacin and Formoterol ) + Placebo DPIApproved
80
Ampreloxetine + PlaceboPhase 3
72
ampreloxetine + PlaceboPhase 3
72
ampreloxetine + PlaceboPhase 3
72